Liquidia's lead product could face limits after the court ruled it violated 2 valid patent claims. Some claims were invalid, and Liquidia plans to appeal, but United Therapeutics seeks an order restricting Yutrepia.
Yutrepia is Liquidia's lead product, so limits on its use could shrink the business it can do with the medicine. Liquidia plans to appeal and remove PH-ILD from the label, but the court may still restrict the product's availability.
United Therapeutics won on 2 patent claims and asked for an order restricting Yutrepia. Other asserted claims were invalid, making this a partial win, but the court's ruling supports its effort.
Follow Liquidia Corp. (LQDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LQDA